Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Grifols SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10
Grifols SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Grifols SA, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12
Partnerships 14
Araclon Biotech Enters into Agreement with TFS International 14
Grifols and GigaGen Enter into Research Agreement 15
Grifols Enters into Agreement with MassBiologics 16
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 17
Licensing Agreements 18
Grifols Enters Into Licensing Agreement With Aradigm 18
ThromboGenics Enters into Licensing Agreement with Grifols 20
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 21
Equity Offering 22
Grifols to Invest USD4 Million in AlbaJuna Therapeutics 22
TiGenix Completes Private Placement Of Shares For US$16.2 Million 23
Debt Offering 24
Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 24
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 25
Acquisition 26
Grifols Shared Services North America Acquires Biotest for USD286 Million 26
Grifols Shared Services North America Acquires 51% Stake in Goetech (MedKeeper) 27
Grifols Acquires 43.96% Stake in GigaGen for USD35 Million 28
Grifols Acquires 49% Stake in Access Biologicals for USD51 Million 29
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 30
Grifols Acquires 47.58% Stake in Alkahest for USD37.5 Million 31
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 32
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 33
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 34
Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 35
Grifols Acquires 51% Stake In Araclon Biotech 36
Grifols SA – Key Competitors 37
Grifols SA – Key Employees 38
Grifols SA – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 44
Strategy And Business Planning 44
Sep 24, 2018: Grifols Announces the Opening of Biotest Pharmaceuticals Corporation’s Newest Plasma Donor Center in Bowling Green, Ohio 44
Financial Announcements 45
Jul 27, 2018: Grifols increases net profits by 15% to EUR 319 million, with sustained operational revenue growth of 7% 45
May 03, 2018: Grifols increases its net profit by 7% to Euros 143 million and delivers significant growth in organic sales 50
Nov 02, 2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million 53
Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions 57
May 03, 2017: Bioscience Division sales increase 15% to drive Grifols’ revenue growth by 11% to Euros 1,062 million 63
Feb 28, 2017: Grifols’ revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division 67
Corporate Communications 75
Apr 17, 2018: Grifols donates over 25 million international units of blood clotting factor in 2017 75
Apr 17, 2017: Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program 76
Legal and Regulatory 77
Jun 08, 2018: Grifols’ Building Receives LEED Certification 77
Mar 19, 2018: Regeneron Pharmaceuticals Announce Regarding Novartis Complaint on ‘688 Patent 78
Government and Public Interest 79
Oct 08, 2018: Grifols Delivers Promise of Advancing Plasma-derived Medicines through Innovative Vision and Donor Support 79
Sep 22, 2017: An ISCIII researcher awarded for her work on Alpha-1 Antitrypsin Deficiency (DAAT) 80
Jun 24, 2017: Grifols Awards One Million Dollar Grant to Support the Alpha-1 Foundation’s John W. Walsh Research Fund 81
Product News 82
Jun 22, 2017: Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples 82
Other Significant Developments 83
Jul 05, 2018: Grifols, the newest angel of elBullifoundation 83
Jun 28, 2018: Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2017 84
May 25, 2018: Grifols culminates a year of growth and approves the distribution of a record EUR 265 million in dividends 85
May 23, 2018: Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency 87
Appendix 88
Methodology 88
About GlobalData 88
Contact Us 88
Disclaimer 88
Grifols SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Grifols SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Grifols SA, Deals By Therapy Area, 2012 to YTD 2018 9
Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10
Grifols SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12
Araclon Biotech Enters into Agreement with TFS International 14
Grifols and GigaGen Enter into Research Agreement 15
Grifols Enters into Agreement with MassBiologics 16
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 17
Grifols Enters Into Licensing Agreement With Aradigm 18
ThromboGenics Enters into Licensing Agreement with Grifols 20
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 21
Grifols to Invest USD4 Million in AlbaJuna Therapeutics 22
TiGenix Completes Private Placement Of Shares For US$16.2 Million 23
Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 24
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 25
Grifols Shared Services North America Acquires Biotest for USD286 Million 26
Grifols Shared Services North America Acquires 51% Stake in Goetech (MedKeeper) 27
Grifols Acquires 43.96% Stake in GigaGen for USD35 Million 28
Grifols Acquires 49% Stake in Access Biologicals for USD51 Million 29
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 30
Grifols Acquires 47.58% Stake in Alkahest for USD37.5 Million 31
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 32
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 33
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 34
Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 35
Grifols Acquires 51% Stake In Araclon Biotech 36
Grifols SA, Key Competitors 37
Grifols SA, Key Employees 38
Grifols SA, Other Locations 39
Grifols SA, Subsidiaries 39
List of Figures
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10